In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS gives thumbs-up to PET/Alzheimer’s coverage

This article was originally published in The Gray Sheet

Executive Summary

Final decision memo aligns with draft decision to cover the scans in a practical clinical trial and for differentiating between Alzheimer's disease and fronto-temporal dementia in patients that have been evaluated for other causes of dementia and still have uncertain clinical symptoms (1"The Gray Sheet" June 24, 2004, p. 6). The national coverage decision is the first reviewed under Medicare Modernization Act requirements for a draft decision posting followed by a 30-day comment period, and implementation of a final policy within 90 days of posting a final decision memo...

You may also be interested in...



Medicare Will Cover PET To Distinguish Alzheimer’s From Other Dementia

CMS' decision to provide national coverage of FDG-PET imaging for some suspected dementia patients corresponds with the Neuroimaging Work Group of the Alzheimer's Association's consensus position

EU Health Program To Help Boost Post-Coronavirus Recovery

The EU’s massive economic stimulus package, Next Generation EU, includes a wide-ranging health program that aims to make health systems more resilient to future threats by supporting the development and manufacture of affordable new medicines and vaccines as well as measures to prevent drug shortages.

ASCO 2020: Roche Highlights TIGIT As Tecentriq Bags Another Approval

The Swiss major focused almost exclusively on the benefits of the combination of Tecentriq and its TIGIT inhibitor tiragolumab at ASCO but also celebrated the approval of a Tecentriq/Avastin combo for hepatocellular carcinoma.

UsernamePublicRestriction

Register

AG032815

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel